CLINICAL USE

Prevention and treatment of chronic stable angina

DOSE IN NORMAL RENAL FUNCTION

5–30 mg twice daily

PHARMACOKINETICS

  • Molecular weight                           :211.2
  • %Protein binding                           :Slightly
  • %Excreted unchanged in urine     : 1
  • Volume of distribution (L/kg)       :No data
  • half-life – normal/ESRD (hrs)      :1/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unknown dialysability. Dose as in normal renal function
  • HD                     :Unknown dialysability. Dose as in normal renal function
  • HDF/high flux   :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD      :Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsSildenafil, tadalafil and vardenafil: enhanced hypotensive effect, avoid concomitant use

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia